Ellen Matloff Discusses Genetic Testing and Counseling in Cancer Care
Ellen T. Matloff, MS, CGC, discusses genetic testing, counseling, and the implications of the US Supreme Court decision to ban the patenting of genes.
Watch
Richard Gray on the Safety and Efficacy of 10 Years of Adjuvant Tamoxifen
Richard G. Gray, MA, MSc, discusses results from the randomized, phase III aTTom study that examined 10 years of tamoxifen versus the more standard 5 years.
Low Testosterone in Patients With ALK-Positive Lung Cancer
D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, comments on ALK-positive lung cancer patients with low testosterone.
The Efficacy of Nivolumab in Advanced Melanoma
Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from a phase I trial investigating the anti-PD-1 monoclonal antibody nivolumab.
Treatment With Radium-223 and Chemotherapy for Prostate Cancer
Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.
Maintenance Pazopanib in Ovarian Cancer
Andreas du Bois, MD, discusses the background, rationale, and results for the exploration of maintenance pazopanib as a treatment for patients with advanced ovarian cancer.
Recent Progress on the Molecular Front for the Treatment of Prostate Cancer
A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.
Crizotinib Versus Chemotherapy in ALK-Positive NSCLC
Alice T. Shaw, MD, PhD, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.
Frontline Bevacizumab in Glioblastoma
Mark R. Gilbert, MD, reviews the trial design and findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.
The Mechanism of Action and Development of Moxetumomab Pasudotox
Edward Bradley, MD, gives an overview of the mechanism of action and development of moxetumomab pasudotox, a monoclonal antibody directed at CD22.
The Phase I Trial of IPI-145 in Hematologic Malignancies
Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3KEδ and PI3K-γ.
The Benefit of Generic Drug User Fees
Richard L. Schilsky, MD, from University of Chicago Comprehensive Cancer Center, explains the benefit to generic drug user fees.
The Future of Palbociclib for the Treatment of Breast Cancer
Richard Finn, MD, comments on the future of palbociclib (PD 0332991), a novel oral selective inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), for the treatment of breast cancer.
An Overview of the Practice-Changing Information From the 2013 ASCO Meeting
Sandra Swain, MD, from the Washington Cancer Institute at MedStar Washington Hospital Center, on the practice-changing information from the 2013 ASCO Meeting.
The Efficacy of Lambrolizumab in Advanced Melanoma
Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.
The Development of Prophage G-200 Vaccine for Recurrent Glioblastoma Multiforme
Andrew T. Parsa MD, PhD, describes the development and trial involving prophage G-200, a vaccine for recurrent glioblastoma multiforme.
Sorafenib in RAI-Resistant Differentiated Thyroid Cancer
Marcia Brose, MD, PhD, discusses the rationale, background, and results from the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.
The Benefits of a Breakthrough Therapy Designation
Richard Pazdur, MD, from the FDA’s Center for Drug Evaluation and Research, describes the benefits of a Breakthrough Therapy Designation.
MPDL3280A for Non-Small Cell Lung Cancer
Roy S. Herbst, MD, PhD, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer.
Optimism Surrounding Immunotherapy for Cancer Care
Clifford A. Hudis, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.
Results of a Phase III Trial that Explored Bevacizumab in Recurrent Cervical Cancer
Krishnansu S. Tewari, MD, describes a phase III trial conducted by the Gynecologic Oncology Group exploring treatment with bevacizumab for patients with recurrent cervical cancer.
The Design and Results of the FIRE-3 Trial
Volker Heinemann, MD, PhD, professor, medical oncology, University of Munich in Munich, Germany, discusses the design and results from the FIRE-3 trial at the 2013 ASCO Annual Meeting.
Using Selumetinib in Advanced Uveal Melanoma
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.
Using Paclitaxel Schedules as Adjuvant Therapy for Breast Cancer
Andrew D. Seidman, MD, comments on the findings of the phase III S0221 trial, which compared two schedules of paclitaxel as adjuvant therapy for breast cancer.
Using Vinegar as a Cervical Cancer Screening Tool
Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, describes the use of vinegar (acetic acid) as a cervical cancer screening tool.
The Impact of the Approval of Radium-223
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, comments on the impact of the approval of radium-223 for bone metastases from prostate cancer.
An Overview of the Treatment of Melanoma
Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, gives an overview of the treatment of advanced melanoma at the 2013 ASCO Annual Meeting.
The Uses of Biomarkers in Prostate Cancer Trials
Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of biomarkers in prostate cancer clinical trials.
Early Treatment for HER2-Positive Metastatic Breast Cancer With T-DM1
Mark D. Pegram, MD, describes research into the antibody-drug conjugate T-DM1 (trastuzumab emtansine), following its FDA approval in February as a treatment for HER2-positive metastatic breast cancer.
The Use of Arsenic Trioxide in Acute Promyelocytic Leukemia
Francesco Lo-Coco, MD, Hematology, University Tor Vergata, speaks at the 2012 American Society of Hematology annual meeting about the use of arsenic trioxide in acute promyelocytic leukemia.